Onconova Therapeutics Statistics Share Statistics Onconova Therapeutics has 21M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 21M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 20.84M Failed to Deliver (FTD) Shares 701 FTD / Avg. Volume 0.55%
Short Selling Information The latest short interest is 30.89K, so 0% of the outstanding
shares have been sold short.
Short Interest 30.89K Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1
Valuation Ratios PE Ratio 0 Forward PE -1.23 PS Ratio 0 Forward PS 69.7 PB Ratio 0 P/FCF Ratio 0 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Onconova Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.16,
with a Debt / Equity ratio of 0.
Current Ratio 2.16 Quick Ratio 2.16 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $14.13B Profits Per Employee $-10,407.7B Employee Count 16 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 51.52% in the
last 52 weeks. The beta is 1.35, so Onconova Therapeutics's
price volatility has been higher than the market average.
Beta 1.35 52-Week Price Change 51.52% 50-Day Moving Average 0.8 200-Day Moving Average 0.77 Relative Strength Index (RSI) 36.95 Average Volume (20 Days) 126,338
Income Statement In the last 12 months, Onconova Therapeutics had revenue of 226B
and earned -166,523B
in profits. Earnings per share was -10724841.16.
Revenue 226B Gross Profit -117,238B Operating Income -142,374B Net Income -166,523B EBITDA -142,374B EBIT n/a Earnings Per Share (EPS) -10724841.16
Full Income Statement Balance Sheet The company has 21,338B in cash and 0 in
debt, giving a net cash position of 21,338B.
Cash & Cash Equivalents 21,338B Total Debt n/a Net Cash n/a Retained Earnings -649,154B Total Assets 19.06B Working Capital 8.46B
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -29,792B
and capital expenditures 0, giving a free cash flow of -29,792B.
Operating Cash Flow -29,792B Capital Expenditures n/a Free Cash Flow -29,792B FCF Per Share -1918740.76
Full Cash Flow Statement Margins Gross margin is -51875.22%, with operating and profit margins of -62997.35% and -73682.74%.
Gross Margin -51875.22% Operating Margin -62997.35% Pretax Margin -73682.74% Profit Margin -73682.74% EBITDA Margin -62997.35% EBIT Margin -62997.35% FCF Margin -13182.3%
Dividends & Yields ONTX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for ONTX.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on May 21, 2021. It was a
backward
split with a ratio of 1:15.
Last Split Date May 21, 2021 Split Type backward Split Ratio 1:15
Scores Altman Z-Score -28882.79 Piotroski F-Score 3
